Anonymous
Guest
Anonymous
Guest
Pretty sure their are many of us with CV experience, including heart failure, right? Hmm, what drugs did Diovan compete with? Other ARBs, other ACE's, etc. Can't anyone that puts in the effort learn the heart failure market? Are the skills sets necessary for a hospital rep/account manager so difficult to master? I don't get it.
Also, side note, I thought a pharma company needed TWO double blind, randomized, bla, bla bla to get approval for a medication. LCZ has on study in heart failure in patients with ejection fraction of <35%. Yes, yes, good and meaningful results. But really are guidelines going to change with only 1 study that has not been. I understand a 2nd study is underway in patients with heart failure (EF of > 35%), so at least we should have two studies (albeit different patient populations). However, the 2nd study will not be completed, analyzed and published at the earliest end of 2017. Is this even a hospital drug???? Let the comment come flying. Go.
Also, side note, I thought a pharma company needed TWO double blind, randomized, bla, bla bla to get approval for a medication. LCZ has on study in heart failure in patients with ejection fraction of <35%. Yes, yes, good and meaningful results. But really are guidelines going to change with only 1 study that has not been. I understand a 2nd study is underway in patients with heart failure (EF of > 35%), so at least we should have two studies (albeit different patient populations). However, the 2nd study will not be completed, analyzed and published at the earliest end of 2017. Is this even a hospital drug???? Let the comment come flying. Go.